Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer - OncLive

Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer  OncLive

Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer - OncLive

Click here to get full coverage on IMUNON Advances Revolutionary Ovarian Cancer Treatment to Phase 3 After Strong Survival Data - Stock Titan

IMUNON Advances Revolutionary Ovarian Cancer Treatment to Phase 3 After Strong Survival Data  Stock Titan

IMUNON Advances Revolutionary Ovarian Cancer Treatment to Phase 3 After Strong Survival Data - Stock Titan

Click here to get full coverage on IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - Yahoo Finance

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer  Yahoo Finance

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - Yahoo Finance

Click here to get full coverage on IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup - CancerNetwork

IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup  CancerNetwork

IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup - CancerNetwork

Click here to get full coverage on ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Clinical Trials Arena

ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer  Clinical Trials Arena

ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Clinical Trials Arena

Click here to get full coverage on Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001 - TipRanks

Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001  TipRanks

Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001 - TipRanks

Click here to get full coverage on What is IMNN company’s growth strategy - Post Market Review For 2025 - jammulinksnews.com

What is IMNN company’s growth strategy - Post Market Review For 2025  jammulinksnews.com

What is IMNN company’s growth strategy - Post Market Review For 2025 - jammulinksnews.com

Click here to get full coverage on Dr Thaker on Data for IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer - OncLive

Dr Thaker on Data for IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer  OncLive

Dr Thaker on Data for IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer - OncLive

Click here to get full coverage on IMUNON Rewards Shareholders with 15% Stock Dividend After Breakthrough Ovarian Cancer Trial Results - Stock Titan

IMUNON Rewards Shareholders with 15% Stock Dividend After Breakthrough Ovarian Cancer Trial Results  Stock Titan

IMUNON Rewards Shareholders with 15% Stock Dividend After Breakthrough Ovarian Cancer Trial Results - Stock Titan

Click here to get full coverage on When is IMNN stock expected to show significant growth - Wealth Building Data Feed For Every Investor - jammulinksnews.com

When is IMNN stock expected to show significant growth - Wealth Building Data Feed For Every Investor  jammulinksnews.com

When is IMNN stock expected to show significant growth - Wealth Building Data Feed For Every Investor - jammulinksnews.com

Click here to get full coverage on IMUNON Avoids Nasdaq Delisting: Hearing Panel Approves Compliance Plan Following Key Equity Achievement - Stock Titan

IMUNON Avoids Nasdaq Delisting: Hearing Panel Approves Compliance Plan Following Key Equity Achievement  Stock Titan

IMUNON Avoids Nasdaq Delisting: Hearing Panel Approves Compliance Plan Following Key Equity Achievement - Stock Titan

Click here to get full coverage on Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer - OncLive

Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer  OncLive

Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer - OncLive

Click here to get full coverage on IMUNON to Hold Second Quarter 2025 Financial Results and - GlobeNewswire

IMUNON to Hold Second Quarter 2025 Financial Results and  GlobeNewswire

IMUNON to Hold Second Quarter 2025 Financial Results and - GlobeNewswire

Click here to get full coverage on IMUNON Earnings Call: Latest Phase 3 Data Coming for DNA-Based Ovarian Cancer Immunotherapy - Stock Titan

IMUNON Earnings Call: Latest Phase 3 Data Coming for DNA-Based Ovarian Cancer Immunotherapy  Stock Titan

IMUNON Earnings Call: Latest Phase 3 Data Coming for DNA-Based Ovarian Cancer Immunotherapy - Stock Titan

Click here to get full coverage on Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer - OncLive

Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer  OncLive

Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer - OncLive

Click here to get full coverage on IMUNON Dodges Delisting Risk: Secures 180-Day Nasdaq Extension Plan During Critical Phase 3 Trial - Stock Titan

IMUNON Dodges Delisting Risk: Secures 180-Day Nasdaq Extension Plan During Critical Phase 3 Trial  Stock Titan

IMUNON Dodges Delisting Risk: Secures 180-Day Nasdaq Extension Plan During Critical Phase 3 Trial - Stock Titan

Click here to get full coverage on OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer - OncLive

OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer  OncLive

OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer - OncLive

Click here to get full coverage on Dr Thaker on the Safety of IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer - OncLive

Dr Thaker on the Safety of IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer  OncLive

Dr Thaker on the Safety of IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer - OncLive

Click here to get full coverage on How does IMNN generate profit in a changing economy - Free Stock Selection - jammulinksnews.com

How does IMNN generate profit in a changing economy - Free Stock Selection  jammulinksnews.com

How does IMNN generate profit in a changing economy - Free Stock Selection - jammulinksnews.com

Click here to get full coverage on OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer - ScienceDirect.com

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer  ScienceDirect.com

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer - ScienceDirect.com

Click here to get full coverage on What is IMNN company’s growth strategy - Free Stock Trend Scanner For 2025 - jammulinksnews.com

What is IMNN company’s growth strategy - Free Stock Trend Scanner For 2025  jammulinksnews.com

What is IMNN company’s growth strategy - Free Stock Trend Scanner For 2025 - jammulinksnews.com

Click here to get full coverage on Imunon Announces Reverse Stock Split to Meet Nasdaq Rules - The Globe and Mail

Imunon Announces Reverse Stock Split to Meet Nasdaq Rules  The Globe and Mail

Imunon Announces Reverse Stock Split to Meet Nasdaq Rules - The Globe and Mail

Click here to get full coverage on PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer - CancerNetwork

PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer  CancerNetwork

PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer - CancerNetwork

Click here to get full coverage on Is IMNN stock overvalued or undervalued - Free Stock Trend Scanner With Proven Results - jammulinksnews.com

Is IMNN stock overvalued or undervalued - Free Stock Trend Scanner With Proven Results  jammulinksnews.com

Is IMNN stock overvalued or undervalued - Free Stock Trend Scanner With Proven Results - jammulinksnews.com

Click here to get full coverage on Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More  Yahoo Finance

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance

Click here to get full coverage on Why IMNN stock attracts strong analyst attention - Risk Managed Trade Playbook Signal - beatles.ru

Why IMNN stock attracts strong analyst attention - Risk Managed Trade Playbook Signal  beatles.ru

Why IMNN stock attracts strong analyst attention - Risk Managed Trade Playbook Signal - beatles.ru

Click here to get full coverage on How volatile is IMNN stock compared to the market - Maximize your returns with portfolio optimization - jammulinksnews.com

How volatile is IMNN stock compared to the market - Maximize your returns with portfolio optimization  jammulinksnews.com

How volatile is IMNN stock compared to the market - Maximize your returns with portfolio optimization - jammulinksnews.com

Click here to get full coverage on FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer - Targeted Oncology

FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer  Targeted Oncology

FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer - Targeted Oncology

Click here to get full coverage on Why IMNN stock attracts strong analyst attention - Weekly Top Gainers Forecast Watchlist Released - beatles.ru

Why IMNN stock attracts strong analyst attention - Weekly Top Gainers Forecast Watchlist Released  beatles.ru

Why IMNN stock attracts strong analyst attention - Weekly Top Gainers Forecast Watchlist Released - beatles.ru

Click here to get full coverage on IMUNON Announces Stock Dividend Boosting Shareholder Value - GlobeNewswire

IMUNON Announces Stock Dividend Boosting Shareholder Value  GlobeNewswire

IMUNON Announces Stock Dividend Boosting Shareholder Value - GlobeNewswire

Click here to get full coverage on IMUNON's Major 1:15 Reverse Split Cuts Shares to 2.1M: What Shareholders Must Know - Stock Titan

IMUNON's Major 1:15 Reverse Split Cuts Shares to 2.1M: What Shareholders Must Know  Stock Titan

IMUNON's Major 1:15 Reverse Split Cuts Shares to 2.1M: What Shareholders Must Know - Stock Titan

Click here to get full coverage on Why is IMNN stock attracting strong analyst attention - Achieve rapid portfolio growth with smart picks - jammulinksnews.com

Why is IMNN stock attracting strong analyst attention - Achieve rapid portfolio growth with smart picks  jammulinksnews.com

Why is IMNN stock attracting strong analyst attention - Achieve rapid portfolio growth with smart picks - jammulinksnews.com

Click here to get full coverage on Why is IMNN stock attracting strong analyst attention - Proven strategies for superior portfolio growth - jammulinksnews.com

Why is IMNN stock attracting strong analyst attention - Proven strategies for superior portfolio growth  jammulinksnews.com

Why is IMNN stock attracting strong analyst attention - Proven strategies for superior portfolio growth - jammulinksnews.com

Click here to get full coverage on Imunon, Inc. Advances COVID-19 Vaccine Research with IMNN-101 Study Completion - TipRanks

Imunon, Inc. Advances COVID-19 Vaccine Research with IMNN-101 Study Completion  TipRanks

Imunon, Inc. Advances COVID-19 Vaccine Research with IMNN-101 Study Completion - TipRanks

Click here to get full coverage on So should I buy imnn at $7. What is stock split does that affect the swing trade - AInvest

So should I buy imnn at $7. What is stock split does that affect the swing trade  AInvest

So should I buy imnn at $7. What is stock split does that affect the swing trade - AInvest

Click here to get full coverage on Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges  Yahoo Finance

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Click here to get full coverage on Imunon, Inc.’s Promising Study on IMNN-001 for Ovarian Cancer: A Market Perspective - TipRanks

Imunon, Inc.’s Promising Study on IMNN-001 for Ovarian Cancer: A Market Perspective  TipRanks

Imunon, Inc.’s Promising Study on IMNN-001 for Ovarian Cancer: A Market Perspective - TipRanks

Click here to get full coverage on Should I hold or sell IMNN stock in 2025 - Build wealth faster with consistent investment plans - jammulinksnews.com

Should I hold or sell IMNN stock in 2025 - Build wealth faster with consistent investment plans  jammulinksnews.com

Should I hold or sell IMNN stock in 2025 - Build wealth faster with consistent investment plans - jammulinksnews.com

Click here to get full coverage on Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer - Curetoday

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer  Curetoday

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer - Curetoday

Click here to get full coverage on Is IMNN stock overvalued or undervalued - Financial News Tracker With High Returns - jammulinksnews.com

Is IMNN stock overvalued or undervalued - Financial News Tracker With High Returns  jammulinksnews.com

Is IMNN stock overvalued or undervalued - Financial News Tracker With High Returns - jammulinksnews.com

Click here to get full coverage on Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued - Stocktwits

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued  Stocktwits

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued - Stocktwits

Click here to get full coverage on IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer - Yahoo Finance

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer  Yahoo Finance

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer - Yahoo Finance

Click here to get full coverage on Imunon Stock (IMNN) Rockets on Clinical Trial Results - TipRanks

Imunon Stock (IMNN) Rockets on Clinical Trial Results  TipRanks

Imunon Stock (IMNN) Rockets on Clinical Trial Results - TipRanks

Click here to get full coverage on IMNN Soars 22.6% on Intraday Surge: Biotech Breakthrough or Retail Frenzy? - AInvest

IMNN Soars 22.6% on Intraday Surge: Biotech Breakthrough or Retail Frenzy?  AInvest

IMNN Soars 22.6% on Intraday Surge: Biotech Breakthrough or Retail Frenzy? - AInvest

Click here to get full coverage on What are the latest earnings results for IMNN - Post Market Picks With Low Risk - jammulinksnews.com

What are the latest earnings results for IMNN - Post Market Picks With Low Risk  jammulinksnews.com

What are the latest earnings results for IMNN - Post Market Picks With Low Risk - jammulinksnews.com

Click here to get full coverage on Imunon Announces 15% Stock Dividend Approval - TipRanks

Imunon Announces 15% Stock Dividend Approval  TipRanks

Imunon Announces 15% Stock Dividend Approval - TipRanks

Click here to get full coverage on Celsion (IMNN) Trading Halted Due to Anticipated News Announcement | IMNN Stock News - GuruFocus

Celsion (IMNN) Trading Halted Due to Anticipated News Announcement | IMNN Stock News  GuruFocus

Celsion (IMNN) Trading Halted Due to Anticipated News Announcement | IMNN Stock News - GuruFocus

Click here to get full coverage on IMNN expands ATM program to $10M; $8.18M capacity remains | PCAR SEC Filing - Form 8-K - Stock Titan

IMNN expands ATM program to $10M; $8.18M capacity remains | PCAR SEC Filing - Form 8-K  Stock Titan

IMNN expands ATM program to $10M; $8.18M capacity remains | PCAR SEC Filing - Form 8-K - Stock Titan

Click here to get full coverage on What drives IMNN stock price - Dynamic portfolio growth - Autocar Professional

What drives IMNN stock price - Dynamic portfolio growth  Autocar Professional

What drives IMNN stock price - Dynamic portfolio growth - Autocar Professional

Click here to get full coverage on When is IMNN stock expected to show significant growth - Discover stock picks with superior returns - jammulinksnews.com

When is IMNN stock expected to show significant growth - Discover stock picks with superior returns  jammulinksnews.com

When is IMNN stock expected to show significant growth - Discover stock picks with superior returns - jammulinksnews.com

Click here to get full coverage on IMUNON, Inc. Announces 1-for-15 Reverse Stock Split Effective July 25, 2025 - Quiver Quantitative

IMUNON, Inc. Announces 1-for-15 Reverse Stock Split Effective July 25, 2025  Quiver Quantitative

IMUNON, Inc. Announces 1-for-15 Reverse Stock Split Effective July 25, 2025 - Quiver Quantitative

Click here to get full coverage on IMUNON Announces Reverse Stock Split - GlobeNewswire

IMUNON Announces Reverse Stock Split  GlobeNewswire

IMUNON Announces Reverse Stock Split - GlobeNewswire

Click here to get full coverage on Phase 3 Biotech IMUNON Raises $9.75M: Strategic Private Placement Fuels DNA Immunotherapy Development - Stock Titan

Phase 3 Biotech IMUNON Raises $9.75M: Strategic Private Placement Fuels DNA Immunotherapy Development  Stock Titan

Phase 3 Biotech IMUNON Raises $9.75M: Strategic Private Placement Fuels DNA Immunotherapy Development - Stock Titan

Click here to get full coverage on Breakthrough in Ovarian Cancer Treatment: New Drug Amplifies Immune Response by 62-fold, Phase 3 Trial Begins - Stock Titan

Breakthrough in Ovarian Cancer Treatment: New Drug Amplifies Immune Response by 62-fold, Phase 3 Trial Begins  Stock Titan

Breakthrough in Ovarian Cancer Treatment: New Drug Amplifies Immune Response by 62-fold, Phase 3 Trial Begins - Stock Titan

Click here to get full coverage on IMUNON Presents Positive Phase 2 Translational Data of - GlobeNewswire

IMUNON Presents Positive Phase 2 Translational Data of  GlobeNewswire

Imunon Inc (IMNN)

Price Chart

Key Statistics

Technicals

About IMNN

Latest News

Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer - OncLive

IMUNON Advances Revolutionary Ovarian Cancer Treatment to Phase 3 After Strong Survival Data - Stock Titan

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers